The 'adenobody' approach to viral targeting: Specific and enhanced adenoviral gene delivery

Gene Therapy

Volumn 4, Issue 10, 1997, Pages 1004-1012

  Watkins, S J ^a,b   Mesyanzhinov, V V ^b,c   Kurochkina, L P ^b,c   Hawkins, R E ^a,b  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b Centre for Protein Engineering   (United Kingdom)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Adenovirus; EGF receptor; Phage; scFv; Targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; INTEGRIN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENOVIRUS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 0030831076     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300511     Document Type: Article

References (39)

1. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology, Vol 7- Gene Transfer and Expression Protocols. The Humana Press Inc: Clifton, NJ, 1991, pp 109-127.
2. Quantin B, Perricaudet LD, Tajbakhsh S, Mandel JL. Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci USA 1992; 89: 2581-2584.
3. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
4. Mitani K, Graham FL, Caskey CT. Transduction of human bone marrow by adenoviral vector. Hum Gene Ther 1994; 5: 941-948.
5. Bergelson JM et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
6. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackie viruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
7. 3 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
8. v integrins. Trends Cell Biol 1994; 4: 52-55.
9. v integrins for infection. J Virol 1994; 68: 6811-6814.
10. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75: 477-486.
11. Michael SI et al. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway. J Biol Chem 1993; 268: 6866-6869.
12. Bell GI et al. Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res 1986; 21: 8427-8447.
13. West MA, Bratscher MS, Watts C. Distinct endocytic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J Cell Biol 1989; 109: 2731-2739.
14. Strelkov SV et al. Preliminary crystallographic studies of bacteriophage T4 fibritin confirm a trimeric coiled-coil structure Virology 1996; 219: 190-194.
15. Efimov VP et al. Fibritin encoded by bacteriophage T4 gene wac has a parallel triple-stranded α-helical coiled-coil structure. J Mol Biol 1994; 242: 470-486.
16. Marks JD et al. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222: 581-597.
17. Ward ES et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Eschenchia coli. Nature 1989; 341: 544-546.
18. Skerra A, Pfitzinger I, Pluckthun A. The functional expression of antibody Fv fragments in Escherichia coli: improved vectors and generally applicable purification techniques Bio/Technology 1991; 9: 273-278.
19. Friguet B et al. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Meth 1985; 77: 305-319.
20. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol 1992; 226: 889-896.
21. Nilson BHK, Morling FJ, Cosset FL, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. Gene Therapy 1996; 3: 280-286.
22. Vile R, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Therapy 1994; 1: 88-98.
23. Silver L, Anderson CW. Interaction of human adenovirus serotype 2 with human lymphoid cells. Virology 1988; 165: 377-387.
24. Berkers JAM, Van Bergen EN, Henegouwen PPM, Boonstra J. The effects of receptor density and cell shape on epidermal growth factor binding. J Receptor Res 1992; 12: 71-100.
25. Horowitz SM. Adenoviridae and their replication. In: Fields BN, Knipe DM et al. (eds). Virology. Raven Press: New York, 1990, pp 1679-1715.
26. Etienne-Julan M et al. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992; 73: 3251-3255.
27. Kasahara N, Dozy AM, Kan YW. Tissue specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-1376.
28. Cosset F-L et al. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 1995; 69: 6314-6322.
29. Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995; 92: 9747-9751.
30. Douglas JT et al. Targeted gene delivery by tropism modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
31. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14: 1570-1573.
32. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47: 87-98.
33. Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444-6448.
34. Neri D et al. Engineering recombinant bifunctional antibodies. Tumor Targeting 1995; 1: 189-194
35. Kurucz I et al. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J Immunol 1995; 154: 4576-4582.
36. Hawkins RE et al. Idiotypic vaccination against B cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single chain Fv 'personal' vaccines. Blood 1994; 83: 3279-3288.
37. Hoogenboom HR et al. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 1991; 19: 4133-4137.
38. Takeuchi Y et al. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell J Virol 1994; 68: 8001-8007.
39. Mason DW, Sedgewick JD. Preparation of lymphocyte subpopulations. In: Klaus GGB (ed). Lymphocytes: A Practical Approach. IRL Press: Oxford, 1987, pp 40-42.